AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company has collaborated with Scripps Research, an international company involved in non-profit biomedical research and drug discovery.
It was reported yesterday that the collaboration is aimed at developing new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.
In addition to programs initially named in the collaboration from preclinical to IND stages of development, Scripps Research will present to AbbVie a certain number of preclinical programs of mutual interest per annum for consideration to be included in the collaboration. Both firms will also work together in parallel to advance CD3 bi-specifics against oncology targets nominated by AbbVie. According to the terms of the license agreement, Scripps Research will continue to conduct pre-clinical research and development activities and in some cases, Phase one clinical trials with AbbVie having an exclusive option to further develop and commercialise.
Should AbbVie exercise its option to a given program, Scripps Research is eligible to receive additional payments from AbbVie, including option exercise fees, success-based development and commercial milestone payments, as well as tiered royalties. AbbVie will make an undisclosed upfront payment, as well as a near-term milestone payment upon achievement of certain success criteria.
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study